Liver andbreast cancer are themosttraumaticdiseasesbecause they affectthemajororgansofthebody.
Nanomedicine recentlyemergedas abetteroptionfor the treatmentofthesedeadlydiseases.As a result,
many nanoparticles have been used to treat cancer cell lines. Of the various nanoparticles, zinc oxide
exhibits biocompatibility. Therefore,the aim ofthe present study was to investigate the activity of zinc
oxide nanoparticles (ZnO-NPs) against HepG2 and MCF-7 cells. The NPs (∼13±2nm) were prepared via
a non-protonated chemical route and were well-characterized through standard techniques. The study
showed thattreatment with NPs is notably effective againstthe proliferation of HepG2 and MCF-7 cancer cells in a dose-dependent manner. The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide, a tetrazole) assays revealed the concentration-dependent cytotoxic effects of NPs in range of
2.5–100g/ml. HepG2 and MCF-7 cells were exposed to ZnO-NPs and exhibited a significant reduction
in their cell viability (95% and 96%; p<0.05) in response to a very low concentration (25g/ml) of the
ZnO-NPs;thisfinding was confirmed withFACS (fluorescence-activated cell sorting) data. The reduction
in cell viability in response to NP treatment induces cytotoxicity in the cultured cells. The quantitative
RT-PCR (real-time polymerase chain reaction) results demonstrate that the exposure of HepG2 cells to
ZnO-NPs results in significant upregulation ofthemRNAexpression level of Bax, p53, and caspase-3 and
the down regulation of the anti-apoptotic gene Bcl-2. The NPs were also tested against five pathogenic
bacteria throughthediskdiffusionmethod, andtheir antibacterial activities were compared withthat of
ZnO salt.
การแปล กรุณารอสักครู่..